Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.84+0.02 (+2.78%)
Close on Nov 18, 2026Market cap $212.06MP/E –Yield –
Lineage Cell Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Lineage Cell Therapeutics's total debt was $18.00K at Dec 31, 2017. For fiscal 2017 it was $18.00K, down 85.0% from the year before. The highest annual figure on record is $246.00K in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $18.00K | -85.0% |
| FY2016 | Dec 31, 2016 | $120.00K | -51.2% |
| FY2015 | Dec 31, 2015 | $246.00K | +693.5% |
| FY2014 | Dec 31, 2014 | $31.00K | – |
| FY2013 | Dec 31, 2013 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2017 | Dec 31, 2017 | $18.00K | -85.0% |
| Q3 FY2017 | Sep 30, 2017 | $44.00K | -74.6% |
| Q2 FY2017 | Jun 30, 2017 | $95.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $95.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $120.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $173.00K | – |
See a number that looks wrong?